Don has more than two decades of life sciences industry, consulting and scientific research experience. He has a depth of knowledge in payor systems, and helping organizations develop sound pricing and market access strategies.
Don has more than 20 years of consulting, scientific research and front-line experience in the life sciences industry. He has expertise working across a broad array of therapeutic areas, with a specialized focus in pricing and market access strategy, payor systems, commercialization planning, and diagnostic reimbursement and coverage.
Don has led projects that span the life sciences product development continuum for organizations around the world. Over the course of his career, he has helped life sciences leaders create U.S. and global pricing and contracting strategies for Phase III / launch, and conduct Phase II assessments to inform Phase III planning and protocol development. He has also guided organizations through early phase, in-licensing evaluations for pipeline prioritization and asset acquisition decisions.
Prior to joining Huron, Don worked in the commercialization and outcomes division of ICON Clinical Research, leading the global pricing and market access practice. Previously, Don was the global market access lead in the specialty care and oncology business units at Pfizer, where he launched the first non-small cell lung cancer therapy with a companion diagnostic, XALKORI.
Don sits on the editorial board at In Vivo – Informa, and is a member of the International Society for Pharmacoeconomics and Outcomes Research.
Areas of Expertise
- Business Unit Strategy
- Innovation and Commercialization
- Research and Development Strategy
- Life Sciences
Education & Certifications
- MBA, Arizona State University, Thunderbird School of Global Management
- B.S. University of Pittsburgh
- B.A., University of Pittsburgh